Reduced insulin sensitivity as a marker for acute mountain sickness?

High Altitude Medicine and Biology

Volumn 14, Issue 3, 2013, Pages 240-250

  Spliethoff, Kerstin ^a   Meier, Daniela ^a   Aeberli, Isabelle ^c   Gassmann, Max ^a,d   Langhans, Wolfgang ^a,b   Maggiorini, Marco ^a,c   Lutz, Thomas A ^a   Goetze, Oliver ^a,c,e  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Acute mountain sickness; Dexamethasone; Erythropoietin; Insulin resistance

Indexed keywords

CHOLECYSTOKININ; DEXAMETHASONE; ERYTHROPOIETIN; GLUCOSE; INSULIN;

ACUTE DISEASE; ACUTE MOUNTAIN SICKNESS; ADULT; ALTITUDE; ALTITUDE DISEASE; ARTICLE; CONTROLLED STUDY; HUMAN; HYPOXIA; INSULIN SENSITIVITY; MOUNTAINEERING; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADULT; ALTITUDE; ALTITUDE SICKNESS; ANOXIA; BLOOD GLUCOSE; CHOLECYSTOKININ; DEXAMETHASONE; ENERGY INTAKE; ERYTHROPOIETIN; FEMALE; GLUCOCORTICOIDS; HOMEOSTASIS; HUMANS; HYDROCORTISONE; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTERLEUKIN-6; ISLET AMYLOID POLYPEPTIDE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OXYGEN; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84884743722     PISSN: 15270297     EISSN: 15578682     Source Type: Journal    
DOI: 10.1089/ham.2012.1128     Document Type: Article

References (64)

1. Abdelmannan D, Tahboub R, Genuth S, and Ismail-Beigi F. (2010). Effect of dexamethasone on oral glucose tolerance in healthy adults. Endocrine Practice 16:770-777.
2. Aeberli I, Erb A, Spliethoff K, et al. (2012). Disturbed eating at high altitude: Influence of food preferences, acute mountain sickness and satiation hormones. Eur J Nutr 52:625-635.
3. Amano Y, Lee SW, and Allison AC. (1993). Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin- 1 beta, and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 43:176-182.
4. Bailey DM, Davies B, Milledge JS, Richards M, Williams SR, Jordinson M, and Calam J. (2000). Elevated plasma cholecystokinin at high altitude: Metabolic implications for the anorexia of acute mountain sickness. High Alt Med Biol 1: 9-23.
5. Basnyat B, Lemaster J, and Litch JA. (1999). Everest or bust: A cross sectional, epidemiological study of acute mountain sickness at 4243 meters in the Himalayas. Aviation Space Environ Med 70:867-873.
6. Borges JL, Bilezikian JP, Jones-Leone AR, et al. (2011). A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of avandamet (rosiglitazone/ metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes Metab 13:1036-1046.
7. Bruera E, Moyano JR, Sala R, Rico MA, et al. (2004). Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: A randomized controlled trial. J Pain Symptom Manage 28:381-388.
8. Cheng K, Ho K, Stokes R, Scott C, et al. (2010). Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest 120:2171-2183.
9. Ding H, Liu Q, Hua M, Ding M, Du H, Zhang W, Li Z, and Zhang J. (2011). Polymorphisms of hypoxia-related genes in subjects susceptible to acute mountain sickness. Respiration 81:236-241.
10. Droma Y, Ota M, Hanaoka M, et al. (2008). Two hypoxia sensor genes and their association with symptoms of acute mountain sickness in Sherpas. Aviation Space Environ Med 79:1056-1060.
11. Duplain H, Vollenweider L, Delabays A, Nicod P, Bartsch P, and Scherrer U. (1999). Augmented sympathetic activation during short-term hypoxia and high-altitude exposure in subjects susceptible to high-altitude pulmonary edema. Circulation 99:1713-1718.
12. Eckardt KU, Boutellier U, Kurtz A, Schopen M, Koller EA, and Bauer C. (1989). Rate of erythropoietin formation in humans in response to acute hypobaric hypoxia. J Appl Physiol 66:1785-1788.
13. Findling JW, Raff H, and Aron DC. (2004). The low-dose dexamethasone suppression test: A reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 89:1222-1226.
14. Foskett A, Alnaeeli M, Wang L, Teng R, and Noguchi CT. (2011). The effects of erythropoietin dose titration during high-fat diet-induced obesity. J Biomed Biotech 2011: 373781.
15. Frese F, and Friedmann-Bette B. (2010). Effects of repetitive training at low altitude on erythropoiesis in 400 and 800m runners. Intl J Sports Med 31:382-388.
16. Fried M, and Feinle C. (2002). The role of fat and cholecystokinin in functional dyspepsia. Gut 51:54-57.
17. Gaber T, Schellmann S, Erekul KB, et al. (2011). Macrophage migration inhibitory factor counterregulates dexamethasonemediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4 + T cell proliferation under hypoxia. J Immunol 186:764-774.
18. Goetze O, Fox M, Erb A, et al. (2010). Gastric emptying, dyspeptic symptoms and eating behavior in healthy mountaineers after rapid ascent to 4559M (14957 Ft). Gastroenterology 138:S467.
19. Hackett PH, Roach RC, Wood RA, et al. (1988). Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 59:950-954.
20. Hartmann G, Tschop M, Fischer R, et al. (2000). High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 12:246-252.
21. Heather LC, and Clarke K. (2011). Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 50:598-605.
22. Heianza Y, Hara S, Arase Y, et al. (2011). HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): A longitudinal cohort study. Lancet 378:147-155.
23. Henriksen JE, Alford F, Vaag A, Handberg A, and Beck-Nielsen H. (1999). Intracellular skeletal muscle glucose metabolism is differentially altered by dexamethasone treatment of normoglycemic relatives of type 2 diabetic patients. Metabolism 48: 1128-1135.
24. Hung AM, Sundell MB, Egbert P, et al. (2011). A comparison of novel and commonly-used indices of insulin sensitivity in African American chronic hemodialysis patients. Clin J Am Society Nephrol 6:767-774.
25. Imray C, Wright A, Subudhi A, and Roach R. (2010). Acute mountain sickness: pathophysiology, prevention, and treatment. Prog Cardiovasc Dis 52:467-84.
26. Jackson SJ, Varley J, Sellers C, et al. (2010). Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. High Alt Med Biol 11:217-222.
27. Johnson TS, Rock PB, Fulco CS, Trad LA, Spark RF, and Maher JT. (1984). Prevention of acute mountain sickness by dexamethasone. New England J Med 310:683-686.
28. Julian CG, Subudhi AW, Wilson MJ, Dimmen AC, Pecha T, and Roach RC. (2011). Acute mountain sickness, inflammation and permeability: New insights from a blood biomarker study. J Appl Physiol 111:392-399.
29. Klausen T, Olsen NV, Poulsen TD, Richalet JP, and Pedersen BK. (1997). Hypoxemia increases serum interleukin-6 in humans. Eur J Appl Physiol Occup Physiol 76:480-482.
30. Lanfranchi PA, Colombo R, Cremona G, et al. (2005). Autonomic cardiovascular regulation in subjects with acute mountain sickness. Am J Physiol Heart Circ Physiol 289: H2364-2372.
31. Larsen JJ, Hansen JM, Olsen NV, Galbo H, and Dela F. (1997). The effect of altitude hypoxia on glucose homeostasis in men. J Physiol 504:241-249.
32. Lee MJ, Gong DW, Burkey BF, and Fried SK. (2011). Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: A microarray study. Am J Physiol Endocrinol Metab 300:E571-580.
33. Leshem E, Pandey P, Shlim DR, Hiramatsu K, Sidi Y, and Schwartz E. (2008). Clinical features of patients with severe altitude illness in Nepal. J Travel Med 15:315-322.
34. Levine BD, Yoshimura K, Kobayashi T, Fukushima M, Shibamoto T, and Ueda G. (1989). Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 321:1707-1713.
35. Lippl FJ, Neubauer S, Schipfer S, Lichter N, Tufman A, Otto B, and Fischer R. (2010). Hypobaric hypoxia causes body weight reduction in obese subjects. Obesity 18:675-681.
36. Loeppky JA, Icenogle MV, Maes D, Riboni K, Scotto P, and Roach RC. (2003). Body temperature, autonomic responses, and acute mountain sickness. High Alt Med Biol 4:367-373.
37. Maggiorini M, Buhler B, Walter M, and Oelz O. (1990). Prevalence of acute mountain sickness in the Swiss Alps. BMJ 301:853-855.
38. Mairer K, Wille M, and Burtscher M. (2010). The prevalence of and risk factors for acute mountain sickness in the Eastern and Western Alps. High Alt Med Biol 11:343-348.
39. Mak RH. (1996). Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol 270:F839-844.
40. Marquet P, Lac G, Chassain AP, Habrioux G, and Galen FX. (1999). Dexamethasone in resting and exercising men. I. Effects on bioenergetics, minerals, and related hormones. J Appl Physiol 87:175-82.
41. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, and Turner RC. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419.
42. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, and Duncan AW. (2001). Diagnosing insulin resistance in the general population. Diabetes Care 24:460-464.
43. Miller AH, Spencer RL, Pulera M, Kang S, McEwen BS, and Stein M. (1992). Adrenal steroid receptor activation in rat brain and pituitary following dexamethasone: implications for the dexamethasone suppression test. Biol Psych 32:850-869.
44. Newton R, King EM, Gong W, Rider CF, Staples KJ, Holden NS, and Bergmann MW. (2010). Glucocorticoids inhibit IL- 1beta-induced GM-CSF expression at multiple levels: Roles for the ERK pathway and repression by MKP-1. Biochem J 427:113-24.
45. Pavlicek V, Marti HH, Grad S, et al. (2000). Effects of hypobaric hypoxia on vascular endothelial growth factor and the acute phase response in subjects who are susceptible to high-altitude pulmonary oedema. Eur J Appl Physiol 81:497-503.
46. Pilichiewicz AN, Feltrin KL, Horowitz M, Holtmann G, Wishart JM, Jones KL, Talley NJ, and Feinle-Bisset C. (2008). Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol 103:2613-2623.
47. Porte D Jr., and Williams RH. (1966). Inhibition of insulin release by norepinephrine in man. Science 152:1248-1250.
48. Ratineau C, Roche C, Chuzel F, et al. (1996). Regulation of intestinal cholecystokinin gene expression by glucocorticoids. J Endocrinol 151:137-145.
49. Rizza RA, Mandarino LJ, and Gerich JE. (1982). Cortisol-induced insulin resistance in man: Impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 54:131-138.
50. Rooney DP, Neely RD, Cullen C, Ennis CN, Sheridan B, Atkinson AB, Trimble ER, and Bell PM. (1993). The effect of cortisol on glucose/glucose-6-phosphate cycle activity and insulin action. J Clin Endocrinol Metab 77:1180-1183.
51. Salazar MR, Carbajal HA, Espeche WG, et al. (2011). Relationships among insulin resistance, obesity, diagnosis of the metabolic syndrome and cardio-metabolic risk. Diabetes Vasc Dis Res 8:109-116.
52. Scherrer U, Vollenweider P, Randin D, Jequier E, Nicod P, and Tappy L. (1993). Suppression of insulin-induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation 88:388-394.
53. Shimazu T. (1967). Glycogen synthetase activity in liver: Regulation by the autonomic nerves. Science 156:1256-1257.
54. Siebenmann C, Bloch KE, Lundby C, Nussbamer-Ochsner Y, Schoeb M, and Maggiorini M. (2011). Dexamethasone improves maximal exercise capacity of individuals susceptible to high altitude pulmonary edema at 4559 m. High Alt Med Biol 12:169-177.
55. Silber E, Sonnenberg P, Collier DJ, Pollard AJ, Murdoch DR, and Goadsby PJ. (2003). Clinical features of headache at altitude: A prospective study. Neurology 60:1167-1171.
56. Smith PJ, Cousins DJ, Jee YK, Staynov DZ, Lee TH, and Lavender P. (2001). Suppression of granulocyte-macrophage colony-stimulating factor expression by glucocorticoids involves inhibition of enhancer function by the glucocorticoid receptor binding to composite NF-AT/activator protein-1 elements. J Immunol 167:2502-2510.
57. Sood A, and Ismail-Beigi F. (2010). Effect of dexamethasone on insulin secretion: examination of underlying mechanisms. Endoc Pract 16:763-769.
58. Subudhi AW, Dimmen AC, Julian CG, Wilson MJ, Panerai RB, and Roach RC. (2011). Effects of acetazolamide and dexamethasone on cerebral hemodynamics in hypoxia. J Appl Physiol 110:1219-1225.
59. Wajngot A, Giacca A, Grill V, Vranic M, and Efendic S. (1992). The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci USA 89:6035-6039.
60. Walter RM, Dudl RJ, Palmer JP, and Ensinck JW. (1974). The effect of adrenergic blockade on the glucagon responses to starvation and hypoglycemia in man. J Clin Invest 54:1214-1220.
61. Wang GL, and Semenza GL. (1995). Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230-1237.
62. Westerterp-Plantenga MS, Westerterp KR, Rubbens M, Verwegen CR, Richelet JP, and Gardette B. (1999). Appetite at high altitude'' [Operation Everest III (Comex-'97)]: A simulated ascent of Mount Everest. J Appl Physiol 87:391-399.
63. Wu TY, Ding SQ, Zhang SL, et al. (2010). Altitude illness in Qinghai-Tibet railroad passengers. High Alt Med Biol 11:189-198.
64. Ziaee V, Yunesian M, Ahmadinejad Z, Halabchi F, Kordi R, Alizadeh R, and Afsharjoo HR. (2003). Acute mountain sickness in Iranian trekkers around Mount Damavand (5671 m) in Iran. Wilderness Environ Med 14:214-219.